A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...
A recent clinical trial funded by Swim Across America grant showed that immunotherapy can successfully replace surgery for mismatch repair-deficient (MMRd) solid tumors. This breakthrough treatment enabled 80% of patients to avoid surgery and regain their organs.
Swim Across America has awarded two $450,000 grants to support novel gene and base editing techniques in advanced cancer research. These grants will accelerate the development of potential gene-edited cancer treatments that could transform how we treat patients.
A phase 2 clinical trial conducted at Memorial Sloan Kettering showed a 100% clinical complete response to dostarlimab for advanced rectal cancer. Swim Across America's early-stage grant funding supported the trial, which also received funding from other partners.